This $6 Biotech Stock Is Opening the Door to True "Personalized Medicine"

Michael A. Robinson

I told you I'd be back "with a huge profit opportunity."

And I've found a $6 biotech stock that's riding a very powerful trend.

The company is a development-stage biotech firm that develops and markets diagnostic technologies that are used to screen for infectious diseases and monitor a number of cancers.

Its proprietary technology is likely to shake up the $50 billion in vitro diagnostics (IVD) market – and it's doing so in the portions of that market that are growing the fastest. In other words, it's following Rule No. 4 of my five-part strategy for building tech wealth – "Focus on Growth."

This technology puts us one step closer to true "personalized medicine" – the customization of treatment regimens and pharmaceuticals for each individual patient.

And when I saw a new report showing that a "knowledgeable outsider" has grabbed 15% of the company's outstanding shares, I knew I couldn't wait any longer to bring this story to you.

So let's take a closer look…

It's Personal

The company I want to recommend to you today, TrovaGene Inc. (Nasdaq: TROV), is a "molecular diagnostics" specialist.

The term refers to the marriage of molecular biology and medical testing. With molecular diagnostics, doctors and researchers can analyze biological markers in a person's genetic code and then diagnose and monitor infectious diseases, detect potential medical risks, and determine which treatments will best serve that patient.

And like I said, it's a technology that opens the door to personalized medicine, which began to take off after the cracking of the human genome.

TrovaGene's know-how is organized around both blood and urine tests. They can be used in infectious-disease screening, monitoring and research, oncology treatment, prenatal genetics, and transplant medicine.

TrovaGene's "precision-cancer monitoring" (PCM) technology can be used to detect and measure circulating tumor DNA (ctDNA) from cancer cells. CtDNA can serve as a potential "marker" of the cancer that remains after surgery and could be a way to predict which patients will experience a recurrence.

The San Diego-based company's tests provide data for genetic mutations related to pancreatic, colorectal, lung, and ovarian cancers, among others. And TrovaGene execs say they're protected by patents both issued and pending.

TrovaGene is still a development-stage firm, and so it's working to collaborate with larger biopharmaceutical companies. The resulting clinical studies will ignite revenue and earnings growth over the long haul.

If the company can execute, there's plenty of business to be had …

Join the conversation. Click here to jump to comments…

Michael A. Robinson

About the Author

Browse Michael's articles | View Michael's research services

Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.

… Read full bio